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Translating the A1C Assay
I
n the clinical management of diabetes,
the A1C assay has become indispens-
able. Used worldwide to monitor
chronic glycemia, the assay is an essential
tool to determine whether a patient has
achieved the core goal of therapy for dia-
betes: a marked and sustained reduction
in plasma glucose to achieve as close to a
normal level as can be safely attained.
With the publication of the A1c-Derived
Average Glucose (ADAG) study in this is-
sue of Diabetes Care (1), the evolution of
the A1C assay continues and an impor-
tant milestone has been reached. To bet-
ter appreciate this recent report, a brief
and admittedly incomplete historical per-
spective may be useful.
Itwas60yearsagothatAllenetal.(2)
showed that hemoglobin A (which makes
up about 97% of total hemoglobin) con-
tains three minor components, desig-
nated HbA1a, HbA1b, and HbA1c (A1C).
In the decades that followed, we learned
thatahexosemoleculeisattachedtothese
components (3) and that hemoglobin A
actually has two more minor glycated de-
rivatives. The ﬁve altogether comprise
5–7% of the HbA molecule (4).
In the early course of the biochemical
dissection of hemoglobin, Huisman and
Dozy (5) noted, virtually in passing, that
the level of glycated hemoglobin compo-
nents was increased in a few individuals
they studied who happened to have dia-
betes. It took 4 more years, however, for
Rahbar and colleagues (6,7) to document
that diabetes is clearly associated with an
elevation in glycated hemoglobin. The
Rahbar reports stimulated other investi-
gators to conﬁrm these initial ﬁndings
and to seek an explanation for how glu-
cose binds to hemoglobin. It was not for
another few years, in 1972, that Bunn et
al. (8) elegantly showed that the cause of
the increased glycated hemoglobin in di-
abetes, which was predominantly the
A1C component, was a result of excess
nonenzymatic glycation that occurred
throughoutthelifespanofredcellsandin
an essentially irreversible process.
The A1C-diabetes story then shifted
from clinical chemistry to clinical medi-
cine. Koenig et al. (9) were the ﬁrst to
show that A1C levels correlated well with
fasting blood glucose, and they con-
cluded that A1C levels “probably reﬂect
. . . themeandailybloodglucoseconcen-
tration...a n dm a yprovide a better in-
dex of control of the diabetic patient.”
Indeed, soon after their report, many
other investigators conﬁrmed a strong as-
sociationbetweenA1Candglycemiccon-
trol and that the measurement had
clinicalutility(10–15),clearlysurpassing
in utility what was then the conventional
assessmentofmetaboliccontrolovertime
(e.g., signs, symptoms, urine, and blood
glucose levels) (15).
The thorough biochemical experi-
mentsperformedinthe1970sand1980s,
most notably by Mortensen and Christo-
phersen (16), demonstrated that the frac-
tion of A1C in a sample depends on the
glucose levels over a previous period,
along with red cell turnover, reaching a
steady state sometime between 4 and 12
weeks. Such kinetics were supported by
many clinical studies in both type 1 and
type 2 diabetic patients where the A1C
levelwasfoundtocorrelatewellwithglu-
cose regulation (17) or the mean blood
glucose derived over time from multiple
ﬁngersticks (9,15,18–24).
AstheuseoftheA1Ctestgainedtrac-
tion, dozens of different analytical meth-
ods based on different assay principles
(e.g., ion-exchange chromatography, af-
ﬁnity chromatography, immunoassay,
and electrophoresis) were used to mea-
sure glycated hemoglobin. Without a
common reference method and in the ab-
sence of a standardized assay, results var-
ied considerably when the same sample
was tested by different laboratories or
methods or even when the same sample
was tested repeatedly by one methodol-
ogy.Itwasquitecommon,forexample,to
have values ranging from 4.0 to 8.1% on
the same blood sample (25). In addition,
the assays used then (and even now) in
clinical medicine not only measured A1C
itself but also more or lesser amounts of
the other glycated hemoglobin compo-
nents, and results were reported as A1C,
HbA1, or total glycated hemoglobin. The
results were also inﬂuenced by other in-
terfering substances in the sample.
The Diabetes Control and Complica-
tions Trial (DCCT) Study Group, recog-
nizing these problems, centralized the
measurement of A1C from the onset of
the study so as to avoid confounding re-
sults if such a key analyte were to be mea-
sured at many sites (26). Also, in
anticipation of the DCCT results, the
American Association for Clinical Chem-
istry (AACC) established, in 1993, an
A1C standardization workgroup to bring
consistency to the measurement of A1C
and to facilitate the traceability of results
back to the DCCT such that these results
couldbedirectlyrelatedtotheriskorpro-
gression of diabetes complications.
After the standardization protocol
was developed, the American Associa-
tion for Clinical Chemistry group was
dissolved and the National Glycohemo-
globin Standardization Program (NGSP)
began in 1996 (27). Brieﬂy, in the NGSP,
the reference method is the measure-
ment of A1C by ion-exchange high-
performance liquid chromatography, as
was used in the DCCT. Manufacturers of
testing equipment can receive NGSP cer-
tiﬁcation if their instruments are cali-
brated to match the results obtained by
the NGSP. Laboratories can also be certi-
ﬁed by the same protocol and thereby
document optimal performance in their
setting.
All this has led to a dramatic reduc-
tion in interlaboratory variability and a
marked improvement in the precision
andcomparabilityofvalues(28).In2007,
99% of all A1C test results in the U.S.
were traceable to those obtained in the
DCCT,withsimilarpercentagesintestre-
sults throughout the U.K. and in Canada
(D. Sacks, personal communication). Al-
though comparable data are not readily
available from other countries, it appears
that much of the world’s A1C testing is
traceable to the DCCT numbers.
Still, issues remain. First, the high-
performance liquid chromatography ref-
erence method used by the NGSP is
somewhat nonspeciﬁc in that the meth-
odology, like many others, measures
morethanjustA1Cinasample.Although
this problem is obviated by the consistent
use of one reference method, in the world
of clinical chemistry, this situation is
“metrologically unsound.” Second, al-
though most methods used worldwide
are NGSP certiﬁed, there are other stan-
dardization programs, most notably in
Japan (29) and in Sweden (30). Thus,
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ization program.
Both of these issues led the Interna-
tional Federation of Clinical Chemistry
and Laboratory Medicine (IFCC) in 1995
to embark on the development of a refer-
ence method that would be very speciﬁc,
i.e., only measures A1C, and that could
lead to worldwide standardization based
on a metrologically sound international
measurement system (31). Not only did
the IFCC succeed (32,33) in developing
such an assay but the reference method
has been approved by all of their member
societies, and a global network of refer-
ence laboratories has been established
(33).
But progress often brings other difﬁ-
culties and problems. First, the IFCC
method is very complicated, requires
costly equipment (a mass spectrometer),
and is very expensive. Thus, as with
many other reference methods, it cannot
be used by a clinical laboratory to mea-
sure A1C in routine samples. That means
it can only be used to calibrate labora-
tory instruments that measure A1C as
before, i.e., by any one of a wide variety
of methods. Although disappointing, this
does not diminish the virtue of now hav-
ing a much more robust standardization
program.
Second, and much more important,
since the new reference method measures
A1C itself, and thus non-A1C compo-
nents are no longer detected, the normal
range for A1C is reduced—by about two
percentage points lower than that cur-
rently reported. Moreover, the IFCC rec-
ommended (to be metrologically correct)
that A1C be expressed in millimoles A1C
per mole of total hemoglobin; this would
resultinanormalrangeofaround29–43
mmol A1C/mol hemoglobin (34).
A shift to lower A1C percentages
would no doubt be intolerably confusing
and likely lead to a deterioration in glyce-
mic control (35), but a wholesale shift to
the IFCC units would surely create may-
hem.Althoughonecouldclearlyprogram
a laboratory instrument to convert the
new IFCC values to DCCT-derived val-
ues,theIFCCmaintainedthattheexpres-
sion of an analyte as a percentage is not
metrologicallysoundandthusshouldnot
be used. In response to the direction pro-
posedbytheIFCC,anAmericanDiabetes
Association/European Association for the
Study of Diabetes/International Diabetes
Federation workgroup was formed (in-
cluding some of the IFCC leadership) to
make recommendations on how this im-
pending crisis could be avoided (36).
What emerged was not only the rec-
ommendation that DCCT-derived num-
bers should be maintained if possible but
also that an international study should
commence to look more closely at the re-
lationship between A1C and mean blood
glucose. If the study was “successful,” at
least we could adopt an A1C-derived unit
(e.g., “estimated average glucose” in mil-
ligrams per deciliter or millimoles per
liter) that would obviate the IFCC ob-
jection to having laboratory results ex-
pressed as a percentage. This path
forward was then ratiﬁed in an ofﬁcial
consensus statement issued by all four
organizations (37).
Therationaleforanotherstudyexam-
ining the relationship between mean
bloodglucoseandA1Cstemmedfromthe
belief that the previously published re-
ports used a variety of measures of glu-
cose concentration, recruited only small
numbers of subjects (and mostly those
with type 1 diabetes), performed mea-
surements over a relatively short time
period,and,mostnotably,performedrel-
atively infrequent sampling of blood glu-
cose (mostly during the daytime). For
example, the often-cited conversion table
in the American Diabetes Association
Standards of Medical Care in Diabetes—
2007 (38) was based on very limited cap-
illary glucose sampling in the DCCT, and
the study was actually not intended to es-
tablish the relationship between average
glucose and A1C. Thus, greater conﬁ-
dence was needed that A1C truly repre-
sents an average glucose.
The results of the international study
are now reported (1) and conﬁrm and ex-
tend previous ﬁndings. The strengths of
the study are that it examined the rela-
tionship between average glucose and
A1C across a wide spectrum of A1C val-
ues—from 5% to as high as 13%—and
in more people than ever before studied.
Also, both normal subjects and subjects
with type 1 and type 2 diabetes were en-
rolled in numbers sufﬁcient to conclude
that the relationship between the two
variables was consistent between these
subgroups and also in relation to other
important variables (i.e., age, ethnicity,
smoking). Finally, the study obtained
2,700 glucose measurements in each
participant, which is far greater than the
number obtained in nearly all previous
studies. The results clearly support the
hypothesis that there is a strong linear re-
lationship between mean blood glucose
and A1C, with a coefﬁcient of correlation
(R
2) of 0.84.
The data from ADAG indicate that at
any mean glucose or A1C level, there is
some scatter (see Fig. 1 in the ADAG
report), thereby conveying a less than
perfect correlation. Is that primarily due
to measurement error, or does it suggest
that an A1C level reﬂects processes be-
yond a straightforward time and glucose
concentration–dependent glycation of
hemoglobin? Addressing this uncertainty
would require an even larger study con-
ducted ideally at only one site, with more
diverse subjects, uninterrupted continu-
ous glucose monitoring for months at a
time, and, most important, a measure-
ment error much lower than currently
seen. The report by Nathan et al. (39) in
which 24,000 glucose measurements
were done on each participant resulted in
an R
2 (0.81) and regression equation very
similar to that reported in the ADAG
study, suggesting that performing more
measurements will not in itself improve
the correlation.
Thus, we have 16–19% of the vari-
ation unaccounted for, but given that
there is a small measurement error in the
determination of A1C (perhaps 2–5%),
and a larger coefﬁcient of variation in the
measurement of glucose (10–20%), the
constraints imposed by methodology can
explain the residual variation.
We are unable, of course, to con-
clude from the study that the relationship
holds for all populations. That is, many
populations (e.g., Asians, Paciﬁc Island-
ers, children) were not studied, and it is
conceivable that the physiology of glyca-
tiondiffersinsuchgroups,althoughthere
is no obvious reason why that would be
so. A recent study (40) that showed a rel-
atively poor correlation between average
glucose and A1C in children should not
raise doubts about the translation of the
ADAG study to other populations. In that
report (40), it is unclear whether the A1C
values were stable throughout the study
and how many glucose measurements
were obtained in each participant, and
there are doubts regarding the precision
and accuracy of the continuous glucose-
monitoring system device used and other
issues (1).
In the ADAG study, the differences
between various ethnic groups were not
statistically signiﬁcant. However, the
study was not adequately powered to de-
tect such differences and, in one group,
the differences came close to being signif-
icant. Although other reports have shown
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at similar levels of glycemia (41,42), in all
the studies, glucose measurements were
very infrequent, the populations studied
were not controlled for hemoglobinopa-
thy, and there were no measures of the
rate of glycation as it relates to ethnicity.
Clearly, this is an area that needs further
investigation.
It is important to note that the ADAG
investigators attempted to study patients
with “stable” glycemia—predeﬁned as a
change in A1C of 1% during the
study—and all but 4% were stable as so
deﬁned. It is not surprising that some
change would occur, particularly since
patients were doing considerably more
self-monitoringthaninreallife.However,
a 1% change with a baseline of 11% has
implications different from those associ-
ated with a similar change at 7%. How-
ever, the investigators quite rightly chose
the end-of-study A1C to relate to esti-
mated average glucose (eAG); therefore,
clinicianscanhaveconﬁdencethattheav-
erage glucose reﬂects antecedent glyce-
mia over a 3-month period.
So what does this mean for clinical
practice? At the simplest and most basic
level, when clinicians explain to patients
what A1C “means,” they should have
greater conﬁdence that the common ex-
planation that has essentially been in ef-
fect for decades—“it’s your average blood
glucose over the last few months”—is
true. In addition, knowing one’s average
glucose level should be beneﬁcial to clini-
cians and patients in that the measure of
long-term glucose control (A1C) can reli-
ably be conveyed in the same units as
those provided to patients at the time of
diagnosis and the values obtained from
patient self-monitoring.
Finally, we have a new opportunity
for (re)education on the importance of
glycemic control and the seriousness of
diabetes. Because the study results ful-
ﬁlled the a priori criteria, the agreement
forged in the consensus statement from
the European Association for the Study of
Diabetes, International Diabetes Federa-
tion,andIFCC(37)willtakeeffect.Thus,
wehopethatclinicianswhoorderanA1C
testwillreceivealabreportcontainingthe
familiar A1C value, an eAG derived from
that measurement, and a likely-to-be-
ignored IFCC unit (in millimoles per
mol). The American Diabetes Association
andEuropeanAssociationfortheStudyof
Diabetes are planning to begin a compre-
hensive educational effort on knowing
one’saverageglucoseandarepublishinga
new conversion table in guidelines that is
based on the equation derived from the
ADAG study.
Patients may still get confused that
the“average”glucoseontheirownmeters
does not match the eAG. However, this is
also an opportunity to educate patients
aboutﬂuctuationsinglucosethatmayoc-
cur at times different from their own test-
ingschedules.Inaddition,the95%CIsof
eAG for any A1C value imply uncertainty
of the “true” mean—and more so at very
high A1C levels. But it should be remem-
bered that every point estimate in medi-
cine has uncertainty related to laboratory
imprecision and inaccuracy and that this
variation is almost always ignored. If nec-
essary, however, these CIs give clinicians
an opportunity to present patients a
“range” in which their average glucose
lies.
Another potential limitation of the
study is the speciﬁc and careful exclusion
ofindividualswithconditionslikelytoaf-
fect A1C, e.g., hemoglobinopathy. Inade-
quate recognition of the latter in clinical
practice remains a limitation to the inter-
pretation of A1C and will thereby limit
the utility of discussing eAG in such
patients.
Despite the limitations discussed
above, the study by Nathan and col-
leagues (1) is likely to remain a key refer-
ence regarding the relationship between
A1C and average glucose. To be sure, the
termA1C,alongwithitscurrentunitsand
normal range, will not vanish or change.
Also, whatever instrument and assay is
used in a clinical laboratory will continue
to remain the same, even though the ref-
erence method used for calibration will
now be more precise. A provider wedded
toconveyinganA1Ctohisorherpatients
will certainly be able to continue doing
so. But for those interested in adding an-
other strategy to improve outcomes, we
now have a new term that will likely be
easiertoexplaintopatientsandtoconvey
more meaning and importance to glucose
control.
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